Nordea Investment Management’s Natus Medical Inc NTUS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-215,045
Closed -$5.59M 997
2022
Q1
$5.59M Buy
215,045
+3,159
+1% +$77.1K 0.01% 560
2021
Q4
$5.09M Sell
211,886
-2,714
-1% -$67K 0.01% 585
2021
Q3
$5.45M Sell
214,600
-1,720
-0.8% -$43.8K 0.01% 586
2021
Q2
$5.62M Buy
216,320
+19,656
+10% +$535K 0.01% 589
2021
Q1
$5.04M Sell
196,664
-7,430
-4% -$190K 0.01% 589
2020
Q4
$4.09M Buy
204,094
+9,434
+5% +$185K 0.01% 609
2020
Q3
$3.35M Sell
194,660
-190,220
-49% -$3.6M 0.01% 587
2020
Q2
$8.27M Buy
+384,880
New +$8.81M 0.01% 527
2018
Q3
Sell
-87,746
Closed -$3.03M 1257
2018
Q2
$3.03M Sell
87,746
-12,431
-12% -$436K 0.01% 652
2018
Q1
$3.37M Buy
100,177
+36,110
+56% +$1.14M 0.01% 529
2017
Q4
$2.45M Buy
64,067
+3,621
+6% +$145K 0.01% 616
2017
Q3
$2.27M Buy
60,446
+8,583
+17% +$303K 0.01% 615
2017
Q2
$1.93M Buy
51,863
+11,792
+29% +$426K ﹤0.01% 625
2017
Q1
$1.57M Buy
+40,071
New +$1.5M ﹤0.01% 647

Other funds holding NTUS

Nordea Investment Management's NTUS Position: Q2 2022 in Review

Nordea Investment Management sold out of Natus Medical Inc (NTUS) in Q2 2022, closing a stake of 215,045 shares — an estimated $5.59M sold.

Nordea Investment Management first reported a position in NTUS in Q1 2017 and held it in 14 quarters. The position peaked at $8.27M in Q2 2020. 186 funds tracked by Wall St. Rank hold NTUS as of Q2 2022.

  • Nordea Investment Management reported no remaining Natus Medical Inc position as of Q2 2022 after selling out during the quarter.
  • Nordea Investment Management sold 215,045 Natus Medical Inc shares in Q2 2022, an estimated $5.59M.
  • Nordea Investment Management first reported a position in Natus Medical Inc in Q1 2017 and held it in 14 quarters.
  • Nordea Investment Management's Natus Medical Inc position peaked at $8.27M in Q2 2020.
  • 186 funds tracked by Wall St. Rank held Natus Medical Inc as of Q2 2022.

Based on Nordea Investment Management's 13F filing for Q2 2022, filed 9 Aug 2022.